Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
2019
Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effect...
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
14
References
5
Citations
NaN
KQI